LEADER 00675nam a22002051 4500 001 991004265233107536 005 20230223115625.0 008 930725s1958 sp 001 0 spa 040 $aBibl. Interfacoltà T. Pellegrino$bita 080 $a794.1 100 1 $aMarimón, Luis de$0490442 245 10$aGran torneo de Kemeri, 1937 /$cL. de Marimón y B. López Esnaola 260 $aMadrid :$bRicardo Aguilera,$c1958 300 $a246 p. ;$c16 cm 650 4$aScacchi$xTornei 700 1 $aLópez Esnaola, Benito 830 0$aColeccion Los Grandes Certámenes del Ajedrez ;$v3 912 $a991004265233107536 996 $aGran torneo de Kemeri, 1937$93376119 997 $aUNISALENTO LEADER 02130nam 2200505Ia 450 001 9910795999103321 005 20230705223546.0 010 $a0-19-535629-2 010 $a1-280-55876-8 010 $a0-585-32788-2 010 $a0-19-515866-0 035 $a(CKB)24235089400041 035 $a(Au-PeEL)EBL241471 035 $a(CaPaEBR)ebr10086898 035 $a(CaONFJC)MIL55876 035 $a(OCoLC)45844538 035 $a(MiAaPQ)EBC241471 035 $a(EXLCZ)9924235089400041 100 $a19950914d1996 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$a"There are no slaves in France" $ethe political culture of race and slavery in the Ancien Regime /$fSue Peabody 210 1$aNew York :$cOxford University Press,$d1996. 215 $a1 online resource (x, 210 pages) $cillustrations 320 $aIncludes bibliographical references and index. 327 $aIntroduction; 1. Slavery in France: The Problem and Early Responses; 2. The Case of Jean Boucaux v. Verdelin: Fashioning the National Myth of Liberty; 3. The Impact of the Declaration of 1738: Nantes, La Rochelle, and Paris; 4. Notions of Race in the Eighteenth Century; 5. Crisis: Blacks in the Capital, 1762; 6. Antislavery and Antidespotism: 1760-1771; 7. The Police des Noirs, 1776-1777; 8. Erosion of the Police des Noirs; Epilogue; Notes; Bibliography; Index 606 $aRacism$zFrance$xHistory$y18th century 606 $aBlack people$xLegal status, laws, etc$zFrance$xHistory$y18th century 606 $aPolitical culture$zFrance$xHistory$y18th century 607 $aFrance$xRace relations$xHistory$y18th century 615 0$aRacism$xHistory 615 0$aBlack people$xLegal status, laws, etc.$xHistory 615 0$aPolitical culture$xHistory 676 $a305.896/044/09033 700 $aPeabody$b Sue$f1960-.$01510140 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910795999103321 996 $a"There are no slaves in France"$93742464 997 $aUNINA LEADER 01774nam0 22003371i 450 001 UON00399267 005 20231205104648.863 010 $a83-601-0906-0 100 $a20111031d2006 |0itac50 ba 101 $aeng 102 $aPL 105 $a|||| ||||| 200 1 $aArchaeology of early Northeastern Africa$ein memory of Lech Krzyzaniak$fedited by Karla Kroeper, Marek Chlodnicki. Michal Kobusiewicz 205 $aPoznan : Archaeological Museum$b2006 210 $axxx$d1061 p.$cill. ; 25 cm 215 $aProceedings of the International Symposium organized by the Poznan Archaeological Museum, Institute of Archaeology and Ethnology Polish Academy of Science, Poznan Branch and the International Commission of the Later Prehistory of Northeastern Africa held at the Poznan Archaeological Museum, Poznan Poland, juli 14th-18th 2003 410 1$1001UON00067278$12001 $aStudies in African Archaeology$fSeries editor$ePaul J.J. Sinclair$v9 606 $aArcheologia$xAfrica settentrionale$3UONC022163$2FI 620 $aPL$dPozna?$3UONL001719 676 $a939.7$cSTORIA DEL NORDAFRICA - fino al 640 ca$v21 702 1$aCHLODNICKI$bMarek$3UONV082292 702 1$aKOBUSIEWICZ$bMichal$3UONV205034 702 1$aKROEPER$bKarla$3UONV052310 710 02$aARCHAEOLOGICAL MUSEUM$cPoznan$3UONV205033$0706665 712 $aPoznan Archaeological Museum$3UONV258787$4650 801 $aIT$bSOL$c20250411$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00399267 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI ARCH 245 $eSI AA 30866 7 245 996 $aArchaeology of early Northeastern Africa$91346987 997 $aUNIOR LEADER 06329nam 22009733u 450 001 9910139555703321 005 20230725051122.0 010 $a1-283-24049-1 010 $a9786613240491 010 $a1-4443-4257-6 010 $a1-4443-4254-1 035 $a(CKB)2550000000045840 035 $a(EBL)819297 035 $a(OCoLC)759159254 035 $a(SSID)ssj0000633398 035 $a(PQKBManifestationID)12245060 035 $a(PQKBTitleCode)TC0000633398 035 $a(PQKBWorkID)10619848 035 $a(PQKB)11067818 035 $a(MiAaPQ)EBC819297 035 $a(EXLCZ)992550000000045840 100 $a20131104d2011|||| u|| | 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aClinical Dilemmas in Inflammatory Bowel Disease $eNew Challenges 205 $a2nd ed. 210 $aHoboken $cWiley$d2011 215 $a1 online resource (286 p.) 300 $aDescription based upon print version of record. 311 $a1-4443-3454-9 327 $aClinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment 327 $a8 Prebiotics and synbiotics: panacea or placebo9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids 327 $a17 Steroids in Crohn's disease: do the benefits outweigh the dangers?Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use? 327 $a26 What is the role of biologics in UC?27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions 327 $a34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis?35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease 327 $a41 Does anti-TNF therapy increase the risk of complications of surgery? 330 $aThe second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking 606 $aClinical dilemmas 606 $aInflammatory bowel diseases 606 $aInflammatory Bowel Diseases 606 $aInflammatory bowel diseases - Decision making 606 $aInflammatory bowel diseases -- Decision making 606 $aInflammatory bowel diseases$xDecision making 606 $aInflammatory bowel diseases 606 $aIntestinal Diseases 606 $aGastroenteritis 606 $aGastrointestinal Diseases 606 $aDigestive System Diseases 606 $aDisease 606 $aInflammatory Bowel Diseases 606 $aMedicine$2HILCC 606 $aHealth & Biological Sciences$2HILCC 606 $aGastroenterology$2HILCC 615 4$aClinical dilemmas. 615 4$aInflammatory bowel diseases. 615 4$aInflammatory Bowel Diseases. 615 4$aInflammatory bowel diseases - Decision making. 615 4$aInflammatory bowel diseases -- Decision making. 615 0$aInflammatory bowel diseases$xDecision making. 615 0$aInflammatory bowel diseases. 615 2$aIntestinal Diseases 615 2$aGastroenteritis 615 2$aGastrointestinal Diseases 615 2$aDigestive System Diseases 615 2$aDisease. 615 2$aInflammatory Bowel Diseases 615 7$aMedicine 615 7$aHealth & Biological Sciences 615 7$aGastroenterology 676 $a616.344 700 $aIrving$b Peter$0956256 701 $aSiegel$b Corey A$0956257 701 $aRampton$b David$0457140 701 $aShanahan$b Fergus$0909421 801 0$bAU-PeEL 801 1$bAU-PeEL 801 2$bAU-PeEL 906 $aBOOK 912 $a9910139555703321 996 $aClinical Dilemmas in Inflammatory Bowel Disease$92165084 997 $aUNINA